861841-94-3

Basic information

• Product Name: 1-(5-(benzyloxy)-2-hydroxy-3-nitrophenyl)ethanone
• Synonyms: 1-(5-(benzyloxy)-2-hydroxy-3-nitrophenyl)ethanone;Ethanone, 1-[2-hydroxy-3-nitro-5-(phenylMethoxy)phenyl]-;1-[2-hydroxy-3-nitro-5-(phenylmethoxy)phenyl]Ethanone
• CAS NO: 861841-94-3
• Molecular Formula: C₁₅H₁₃NO₅
• Molecular Weight: 287.26742
• Mol File: 861841-94-3.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 400.3 °C at 760 mmHg
• Flash Point: 195.9 °C
• Appearance: /
• Density: 1.33 g/cm³
• Storage Temp.: 2-8°C
• Solubility: Chloroform, DCM, Ethyl Acetate
• PKA: 7.50±0.38(Predicted)
• CAS DataBase Reference: 1-(5-(benzyloxy)-2-hydroxy-3-nitrophenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-(benzyloxy)-2-hydroxy-3-nitrophenyl)ethanone(861841-94-3)
• EPA Substance Registry System: 1-(5-(benzyloxy)-2-hydroxy-3-nitrophenyl)ethanone(861841-94-3)

Safety Data

• Hazardous Substances Data: 861841-94-3(Hazardous Substances Data)

Usage

Uses

1-(5-Benzyloxy-2-hydroxy-3-nitrophenyl)ethanone is an intermediate in the synthesis of Olodaterol (O262000), a novel inhaled β2-adrenoceptor agonist with a 24h bronchodilatory efficacy.

InChI:InChI=1S/C15H13NO5/c1-10(17)13-7-12(8-14(15(13)18)16(19)20)21-9-11-5-3-2-4-6-11/h2-8,18H,9H2,1H3

Upstream product

• 30992-63-3 5-benzyloxy-2-hydroxyacetophenone 
• 490-78-8 2,5-Dihydroxyacetophenone 
• 100-39-0 benzyl bromide 

Downstream Products

• 861841-93-2 trifluoromethansulfonic acid 2-acetyl-4-benzyloxy-6-nitro-phenyl ester 
• 869478-09-1 8-acetyl-6-(phenylmethoxy)-4H-1,4-benzoxazin-3-one 
• 926319-53-1 8-(bromoacetyl)-6-(phenylmethoxy)-2H-1,4-benzoxazin-3(4H)-one 
• 869478-12-6 8-(2R)-oxirane-6-(phenylmethoxy)-2H-1,4-benzoxazine-3(4H)-one 
• 861841-90-9 1-[2-hydroxy-3-amino-5-(benzyloxy)phenyl]ethanone 

Relevant articles and documents

CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE

The invention provides a class of compounds represented by formula (I), having bifunctional active quaternary ammonium salt structure of a β2-adrenoreceptor agonist and an M receptor antagonist, a pharmaceutically acceptable salt, solvate, and optical isomer thereof. A pharmaceutical composition comprising such a compound with quaternary ammonium salt structure, a method for preparing such a compound with quaternary ammonium salt structure and an intermediate thereof, and uses thereof in treating pulmonary disorders are also provided. The compounds of the invention have high selectivity to the M receptor subtype, and have less adverse reaction and lower toxic and side effects in the treatment of pulmonary diseases such as COPD and asthma.

PROCESS FOR THE MANUFACTURING OF BETA MIMETICS

The invention relates to a method for producing betamimetics of formula (1), wherein in which n represents 1 or 2; R1 represents hydrogen, halogen, C1-4-alkyl or O—C1-4-alkyl; R2 represents hydrogen, halogen, C

PROCESS FOR THE MANUFACTURING OF BETAMIMETICS

The present invention relates to a process for preparing betamimetics of formula 1, wherein n denotes 1 or 2; R1 denotes hydrogen, halogen, C1-4-alkyl or O—C1-4-alkyl; R2 denotes hydrogen, halogen, C1-4/su